摘要B细胞淋巴瘤(BCL)-2是参与细胞凋亡信号通路的重要蛋白，可在体内发挥抑制细胞凋亡的重要作用，与肿瘤的发生、发展及耐药性的产生密切相关。高选择性的口服抗凋亡蛋白BCL-2抑制剂，venetoclax可以通过重启肿瘤细胞凋亡发挥抗肿瘤作用。目前，venetoclax单药或者联合其他药物治疗血液系统恶性肿瘤已经取得了重要进展。笔者现就venetoclax在慢性淋巴细胞白血病(CLL)、套细胞淋巴瘤(MCL)、弥漫大B细胞淋巴瘤(DLBCL)、滤泡淋巴瘤(FL)、多发性骨髓瘤(MM)、急性髓细胞白血病(AML )等多种血液系统恶性肿瘤治疗中的临床研究新进展进行阐述。

abstractsB-cell lymphoma (BCL)-2 is an important protein involved in cell apoptosis signal pathway. It plays an important role in inhibiting cell apoptosis in vivo and is closely related to the occurrence and development of tumors, as well as the production of drug resistance. Venetoclax, as a highly selective oral anti-apoptotic protein BCL-2 inhibitor, can produce anti-tumor effects by restarting tumor cell apoptosis. At present, some important progresses of venetoclax alone or in combination with other drugs in treatment of hematological neoplasms have been made. This article will present the new clinical research progress of venetoclax in treatment of various hematological neoplasms, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), and acute myeloid leukemia (AML).